KRAS Mutant Allele-Specific Imbalance (MASI) Assessment in Routine Samples of Patients With Metastatic Colorectal Cancer

Journal of Clinical Pathology - United Kingdom
doi 10.1136/jclinpath-2014-202761
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer

Clinical Cancer Research
Cancer ResearchOncology
2010English

Different Metastatic Pattern According to the KRAS Mutational Status and Site-Specific Discordance of KRAS Status in Patients With Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2012English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

KRAS Mutation Analysis of Single Circulating Tumor Cells From Patients With Metastatic Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

Mutations in KRAS Codon 12 Predict Poor Survival in Chinese Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2017English

Allele-Specific Inhibitors Inactivate Mutant KRAS G12C by a Trapping Mechanism

Science
MultidisciplinaryPhilosophy of ScienceHistory
2016English

Prevalence of KRAS, BRAF, PI3K and EGFR Mutations Among Asian Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2015English

P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2016English

Outcome Analysis of Phase I Trial Patients With Metastatic KRAS and/or TP53 Mutant Non-Small Cell Lung Cancer

Oncotarget
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy